Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Former Pfizer R&D President Joins Frequency Therapeutics

By Frequency Therapeutics | March 31, 2017

Frequency Therapeutics, a company developing a pipeline of drugs by activating progenitor cells within the body, announced the appointment of John LaMattina, Ph.D. as a senior advisor to the CEO, and a member of the Scientific Advisory Board.

“As a highly-regarded industry veteran, John brings us a wealth of knowledge and expertise,” said David Lucchino, President, Co-Founder and CEO of Frequency. “John has already begun to help us accelerate the development of our pipeline of product candidates for hearing restoration.”

LaMattina previously was president of Pfizer Global Research and Development and senior vice president of Pfizer, Inc. During LaMattina’s leadership tenure, Pfizer discovered and developed several important new medicines including Tarceva, Chantix, Zoloft (PTSD), Selzentry and Lyrica along with a number of other medicines currently in late stage development for cancer, rheumatoid arthritis and pain.

LaMattina is the author of numerous scientific publications and U.S. patents, and is the author of “Drug Truths: Dispelling the Myths About Pharma R&D.” He currently serves as an independent mon-executive director at PureTech Health.

“It is my pleasure to join Frequency Therapeutics as it begins clinical development of a treatment for hearing loss,” said LaMattina. “The team has made remarkably rapid progress, and Frequency’s Progenitor Cell Activation platform presents an exceptional opportunity to develop a wide range of new disease-modifying therapies for hearing and other areas throughout the body.”

(Source: Business Wire)

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE